Effect of dupilumab on asthma control and asthma-related quality of life in patients with uncontrolled, moderate-to-severe type 2 asthma: TRAVERSE OLE study
W. Busse (Madison, United States), I. Pavord (Oxford, United Kingdom), J. Corren (Los Angeles, United States), A. Menzies-Gow (London, United Kingdom), E. Heffler (Milan, Italy), J. Msihid (Chilly-Mazarin, France), S. Siddiqui (Tarrytown, United States), D. Lederer (Tarrytown, United States), M. Hardin (Cambridge, United States), Y. Zhang (Tarrytown, United States), A. Khan (Chilly-Mazarin, France), J. Jacob-Nara (Bridgewater, United States), Y. Deniz (Tarrytown, United States), P. Rowe (Bridgewater, United States)
Source: International Congress 2022 – Update on clinical trials in allergy, asthma and COPD
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Busse (Madison, United States), I. Pavord (Oxford, United Kingdom), J. Corren (Los Angeles, United States), A. Menzies-Gow (London, United Kingdom), E. Heffler (Milan, Italy), J. Msihid (Chilly-Mazarin, France), S. Siddiqui (Tarrytown, United States), D. Lederer (Tarrytown, United States), M. Hardin (Cambridge, United States), Y. Zhang (Tarrytown, United States), A. Khan (Chilly-Mazarin, France), J. Jacob-Nara (Bridgewater, United States), Y. Deniz (Tarrytown, United States), P. Rowe (Bridgewater, United States). Effect of dupilumab on asthma control and asthma-related quality of life in patients with uncontrolled, moderate-to-severe type 2 asthma: TRAVERSE OLE study. 3209
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|